Regulation of cellular protein phosphatase-1 (PP1) by phosphorylation of the CPI-17 family, C-kinase-activated PP1 inhibitors.

Masumi Eto
Thomas Jefferson University

Follow this and additional works at: https://jdc.jefferson.edu/physfp

Part of the Oncology Commons

Let us know how access to this document benefits you

Recommended Citation

Eto, Masumi, "Regulation of cellular protein phosphatase-1 (PP1) by phosphorylation of the CPI-17 family, C-kinase-activated PP1 inhibitors." (2009). Department of Molecular Physiology and Biophysics Faculty Papers. Paper 7.

https://jdc.jefferson.edu/physfp/7

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Molecular Physiology and Biophysics Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
As submitted to:

Journal of Biological Chemistry

And later published as:

Journal of Biological Chemistry

Volume 284, Issue 51, 18 December 2009, Pages 35273-35277

DOI: 10.1074/jbc.R109.059972

“Regulation of cellular protein phosphatase-1 (PP1) by phosphorylation of the CPI-17 family, C-kinase-activated PP1 inhibitors”

Masumi Eto

Thomas Jefferson University, Department of Molecular Physiology and Biophysics, and Kimmel Cancer Center, 1020 Locust Street, 436 JAH, Philadelphia, PA19107

Phone: 215-503-7891, Fax: 215-503-2073, Email: masumi.eto@jefferson.edu

Running head: CPI-17 family in cellular PP1 regulation

The regulatory circuit controlling cellular protein phosphatase-1 (PP1), an abundant group of Ser/Thr phosphatases, involves phosphorylation of PP1-specific inhibitor proteins. Malfunctions of these inhibitory proteins have been linked to a variety of diseases, including cardiovascular disease and cancer. Upon phosphorylation at Thr38, the 17-kDa PP1 inhibitor protein, CPI-17, selectively inhibits a specific form of PP1, myosin light chain phosphatase (MLCP), which transduces multiple kinase signals into the phosphorylation of myosin-II and other proteins. Here, the mechanisms underlying PP1 inhibition, and the kinase/PP1 crosstalk mediated by CPI-17 and its related proteins, PHI, KEPI, and GBPI, are discussed.

Introduction

The reciprocal activities of protein kinases and phosphatases determine protein phosphorylation levels in cells. PP1 dephosphorylates phospho-Ser/Thr residues of proteins, to regulate multiple signal pathways at various cellular loci (1-3). Cellular PP1 is associated with PP1 regulatory protein/subunits at their PP1-binding site, known as the RVXF motif. The binding of PP1 regulatory proteins thus confers substrate specificity and localization on cellular PP1. Nearly 100 polypeptides have been identified as PP1 regulatory proteins and these account for the wide spectrum of PP1 function (1-3). In addition, eukaryotic cells express several PP1 inhibitor proteins that play important roles in regulating cellular PP1. The first generation of PP1 inhibitor proteins involves inhibitor-1, inhibitor-2, DARPP32 and NIPP-1, which potently inhibit the free catalytic subunit of PP1, but these inhibitor proteins were much less potent toward purified PP1 holoenzymes, MLCP and the glycogen-bound PP1. Therefore, cellular PP1 holoenzymes were thought to undergo subunit dissociation prior to the inhibition of PP1 by the inhibitor proteins (1,2). However, the number of PP1 holoenzymes that do undergo subunit dissociation in cells remains unclear.
MLCP is a trimeric PP1 holoenzyme, consisting of a PP1\(\beta\) isoform and a regulatory complex of MYPT1 (a.k.a. MBS, M110) regulatory and M21 accessory subunits that govern myosin-II phosphorylation (4). MYPT1 and PP1 bind through the MYPT1 KVKF segment, as well as its 8-repeat ankyrin motif at the N-terminal domain (5). Binding of the N-terminal 300-residue domain of MYPT1 is sufficient to allosterically regulate PP1 activity. The MYPT1 C-terminal domain directly binds to substrates, including myosin and ezrin/radixin/moesin (4). MLCP activity is tightly regulated in response to various signals. For example, in smooth muscle, activation of the G-protein coupled receptor inhibits MLCP resulting in increased Ca\(^{2+}\) sensitivity of myosin phosphorylation and contraction, whereas cyclic nucleotide signals can activate MLCP to induce smooth muscle relaxation (6). MLCP inhibition occurs upon MYPT1 phosphorylation at Thr696 and Thr853 (4). On the other hand, cGMP-K can activate MLCP (7). These regulatory signals are MYPT1 isoform-dependent (8), suggesting an important role for MYPT1 in MLCP regulation. In addition, we identified the MLCP inhibitor protein, named CPI-17, which transduces G-protein signals into MLCP inhibition (9,10). Based on sequence similarity, three CPI-17 homologues, PHI, KEPI and GBP1, in the human genome were characterized as PP1 inhibitors (11-13). Each CPI-17 family member carries a PP1 holoenzyme inhibitory (PHIN) domain, where the sequences are >41 % identical to CPI-17 (Fig. 1A). Indeed, all CPI-17 family members potently inhibit MLCP activity, which suggests new avenues for PP1 holoenzyme inhibition. This Minireview will focus on CPI-17 and its homologues, whose amino acid sequences differ significantly from other PP1 inhibitor proteins, highlight critical findings from CPI-17 studies, and discuss the role of other CPI-17 family members in regulating PP1 activity.

Structure and function of CPI-17

Amino acid sequence of CPI-17: The CPI-17 gene (PPP1R14A, chromosome 19) encodes a 147-residue polypeptide where >85 % of the amino acids are identical within mammals (10) (Fig. 1A). A splice variant of CPI-17 (CPI-17\(\beta\)) lacking exon 2 exists in human smooth muscle cells, although whether this form is physiologically relevant is not known (see subsequent section) (14). Zebrafish express a similar gene, although to which CPI-17 family member this gene product is functionally related is unclear. No homologous genes have been detected in fruit fly, nematode, and yeast genes, suggesting that the CPI-17 family emerged at a late stage in evolution. Phosphorylation of CPI-17 at Thr38 is necessary and sufficient to convert the protein into a potent MLCP inhibitor (9,10). No homology is detected between the CPI-17 family and other classes of PP1 inhibitors, such as inhibitor-1 and inhibitor-2, even though phosphorylation is also involved in the function of most other PP1 inhibitor proteins. The CPI-17 structure has three domains: N- and C-terminal tails and the central 86-residue PHIN domain between residues 35 to 120 (Fig. 1A) (15). The sequence surrounding the inhibitory phosphorylation site characterizes the CPI-17 family, and is pseudo palindromic, (basic)-(hydrophobic)-Thr-(hydrophobic)-(basic) (16). Tyr41, Asp42 and Arg43 of CPI-17 are necessary for the inhibitory activity, and also conserved among CPI-17 family members (15). Substitution of Ala at CPI-17 Thr41 accelerates phospho-Thr38 dephosphorylation, the significance of which will be discussed (15). In contrast to the PHIN domain, both the N- and C-terminal tail domains are unique for each CPI-17 family member. The other CPI-17 family members do possess the putative PP1 binding RVXF motif, which is located at the N-terminal tails of PHI, KEPI and GBPI (Fig. 1A, green box) (11-13).

3D structure of CPI-17: Solution NMR studies revealed the 3D structure of unphosphorylated and phospho-CPI-17 PHIN domains (16). The structure of the CPI-17 PHIN domain consists of a loop structure encompassing the phosphorylation site Thr38 (P-loop), followed by a four-helix bundle that stabilizes the P-loop structure (shown in Fig. 1A, bottom) (16). Fig. 2 shows the 3D structural models of unphosphorylated and phospho-CPI-17. In the unphosphorylated form, two paired A/D and B/C helices form a V shape structure with the P-loop situated between the paired helices (Fig. 2, left). Upon Thr38 phosphorylation, the P-loop becomes more solvent exposed, and in doing so, generates torque in the A-helix. This twisting of the A-helix rolls the A-B loop up to align the B/C helices in parallel with the A/D helices (Fig. 2, center). The newly aligned four helices are then stabilized through a hydrophobic core that is created by the rearrangement. The P-loop of phospho-CPI-17 is now displayed on the molecular surface, tethered by Tyr41. Presumably, the anchoring function of Tyr41 is necessary to prevent dephosphorylation of the MLCP active site. The phosphate group at
Thr38 cannot be replaced with Asp, which causes P-loop dislocation with a minimal increase in inhibitory potency, or with Glu, which distorts the overall structure. Furthermore, substitution of a cysteine-derived sulphanic acid side chain at Thr38 cannot mimic phosphorylation. Thus, the phosphate group seems to play a specific role for CPI-17’s potent inhibitory activity beyond only being a trigger of conformational change. The splice variant CPI-17β retains the P-loop and the A/D-helix pair, although whether this isoform can inhibit PP1 or functions as a dominant negative form in the cell is not known. Based on the sequence similarity in the PHIN domain, the structural topology and as such the function is likely conserved for CPI-17 family members.

Selective inhibition of MLCP by phospho-CPI-17: Phospho-CPI-17 selectively inhibits the MLCP complex with an IC\textsubscript{50} value of around 1 nM (17,18). How then can CPI-17 recognize only the PP1 associated with MYPT1 among nearly one hundred other PP1 holoenzymes that exist in cells? Fig. 2 illustrates our current model for the selective inhibition of MLCP by phospho-CPI-17. PP1 associated with MYPT1 is unable to hydrolyze the phospho-Thr38 of CPI-17, so that phospho-CPI-17 forms a stable complex with MLCP (Fig. 2, left). On the other hand, other PP1 holoenzymes are able to dephosphorylate phospho-CPI-17 and neutralize its inhibitory potency. Simply put, the PP1 regulatory subunit determines whether phospho-CPI-17 is an inhibitor or substrate of PP1. A kinetic analysis suggests a mixed inhibition of MLCP is induced by phospho-CPI-17, with K\textsubscript{i} and K\textsubscript{i}' values of 1.9 nM and 5.1 nM, respectively (17). Indeed, computer modeling predicts a direct contact between phospho-CPI-17 and MYPT1 (Fig. 2, right), which may account for CPI-17’s specific inhibition of MLCP (16). Fig. 1B illustrates the electrostatic surface potential of phospho-CPI-17 and the predicted maps for other CPI-17 homologues calculated from sequence alignments. The docking surface of CPI-17 (Fig. 1B left) consists of positively charged residues surrounding an acidic island of phospho-Thr38 (cyan arrow). The positively charged regions around phospho-Thr38 seem to complement the acidic cluster formed by PP1 and the MYPT1 ankyrin repeat domain (5). The pattern of surface potential varies within the CPI-17 family, whereas the negative charge dominates in models of PHI-1 and KEPI structures, and the positive charge is clustered at the edge of GBPI (Fig. 1B). The differences in the structure of the docking surface suggest that each CPI-17 homologue selectively controls a specific subset of target PP1 holoenzymes and cellular events.

Role of CPI-17 in cell signaling

Kinases and phosphatases regulating CPI-17: Multiple kinases and phosphatases are involved in regulating CPI-17 phosphorylation. In smooth muscle, CPI-17 phosphorylation occurs in response to agonist stimulation through activation of PKC, ROCK and ILK (19,20). Indeed, PKC\(\alpha\) and \(\delta\) are the dominant kinases for CPI-17 in pig aorta smooth muscle extracts (21). Also, CPI-17 binds to the regulatory domain of PKC isoforms, including \(\alpha, \varepsilon, \lambda, \zeta,\) and \(\mu\) (22). Zipper-interacting kinase and p21-activated kinase are also known to directly phosphorylate isolated CPI-17 at Thr38 (23,24). Thus, CPI-17 is expected to function as a hub of multiple kinase signals that control MLCP activity. For example, \(\alpha_1\)-adrenergic receptor stimulation produces bi-phasic phosphorylation of CPI-17 through the sequential activation of PKC and ROCK in smooth muscle (25). The G-protein coupled receptor-induced rapid activation of Ca\textsuperscript{2+}-dependent PKC elicits acute CPI-17 phosphorylation, causing MLCP inhibition, which amplifies the Ca\textsuperscript{2+}-calmodulin-dependent myosin light chain kinase signal. Following Ca\textsuperscript{2+} withdrawal, the delayed and sustained activation of ROCK maintains CPI-17 and MYPT1 phosphorylation, causing tonic smooth muscle contraction (25). Thus, the combination of kinase signals confers the profile of smooth muscle force generation through CPI-17 phosphorylation. CPI-17 phosphorylation reversibly declines in response to elevated cAMP/cGMP levels (26), which attenuate PKC and ROCK signals (27). In addition, treatment with a cGMP analog possibly activates unidentified phosphatase(s) that can dephosphorylate CPI-17 (28). In our model, CPI-17 is dephosphorylated by such “other” PP1 complexes (Fig. 2) (18). In addition, purified protein phosphatase 2A and 2C are capable of dephosphorylating CPI-17 (29), suggesting the possible involvement of multiple phosphatases in regulating CPI-17 phosphorylation. Interestingly, PKA is known to phosphorylate and activate PP2A in brain (30), so that CPI-17 dephosphorylation could occur through cAMP/cGMP-activated PP2A. It should be noted that high activity of CPI-17 phosphatase(s) may explain why CPI-17 phosphorylation cannot be detected in thromboxane A2-
stimulated cerebral artery from normal rat (31) or phenylephrine-stimulated mesentery arteries from genetically hypertensive rats (32). In addition to Thr38, purified PKC also phosphorylates Ser12 at the CPI-17 N-terminal tail, while CaMKII preferentially phosphorylates Ser130 at the CPI-17 C-terminal tail (9,33). CPI-17 phosphorylation at Ser128 was also detected in brain tissue extracts (33). However, the physiological relevance of this additional phosphorylation at both tails remains to be investigated. The possibility that these sites are involved in regulating other target subsets, as reported for the phosphorylation of DARPP32 at Thr34 and Thr75 that induces the inhibition of PP1 and PKA, respectively (34), cannot be discounted, however.

Expression of CPI-17: CPI-17 is predominantly expressed in mature smooth muscle (10), and higher levels are present in tonic muscles, such as arteries (at 7 µM), compared with phasic muscles, such as ileum, bladder and vas deferens (at 0.8 µM), or cells in neointimal lesions (35,36). CPI-17 is also expressed in embryonic cardiac muscle where smooth-muscle marker proteins are expressed, but its expression disappears in adult tissue (36). Platelet, neuron, endothelium and epithelium also express CPI-17, whose roles in these tissues will be discussed (35-37). Accumulating evidence suggests a correlation between the CPI-17 expression level and the extent of PKC-mediated Ca\(^{2+}\) sensitized force. Selective permeabilization of smooth muscle tissue with Triton X-100 eliminates the contraction induced by PKC activation, and the addition of recombinant CPI-17 restores PKC-mediated contraction (38). The extent of smooth muscle contraction evoked by phorbol ester stimulation depends on the CPI-17 expression level (35). Interestingly, CPI-17 is absent in tissues from the American farm chicken, and as such provides an excellent model of CPI-17-null smooth muscle (39). Stimulation with agonists, PDBu, or G-proteins evokes a marginal extent of the contraction of chicken aortic smooth muscle, suggesting the importance of CPI-17 in agonist-induced smooth muscle contraction (39). Furthermore, fluctuations in CPI-17 signals reportedly occur under pathological conditions, such as hypertension, asthma, inflammation, and diabetes (40-45). For example, CPI-17 expression and phosphorylation are up-regulated in hypoxia-induced pulmonary hypertension (40). CPI-17 up-regulation is also found in airway smooth muscle during inflammation and in diabetic bladder smooth muscle (41,45). In contrast, inflammation causes down-regulation of CPI-17 in intestinal smooth muscle in parallel with a reduction in muscle tone (43). How inflammatory signals trigger this bi-directional regulation of CPI-17 in different smooth muscle tissues remains unknown.

CPI-17 in other cell types: Reversible phosphorylation of myosin is involved in controlling endothelial cell motility and platelet activation. CPI-17 in endothelial cells and platelets translates the activation of PKC and/or ROCK into MLCP inhibition and myosin-II phosphorylation as seen in smooth muscle (46,47). In Purkinje neurons, CPI-17 is involved in long-term synaptic depression (37). The synaptic depression of cerebellar Purkinje cells occurs through PKC-mediated chronic internalization of the AMPA receptor in response to glutamate release. Neutralization of endogenous CPI-17 in Purkinje cells using siRNA or a blocking antibody results in rapid recovery of membrane current upon glutamate stimulation (37), suggesting that metabotropic Glu receptor-induced activation of PKC causes CPI-17 phosphorylation and subsequent MLCP inhibition, thus maintaining AMPA receptor internalization (37). Furthermore, CPI-17 drives cell proliferation by activating the MAP kinase signal pathway (48). Growth factor signals induce phosphorylation of merlin, a product of the neurofibromatosis type-2 gene, which relieves inhibition of the ERK1/2 signal. Merlin is phosphorylated by a subset of protein kinases, including ROCK, PAK and PKC, which are also capable of phosphorylating CPI-17. Overexpression of CPI-17 down- and up-regulates MLCP and merlin phosphorylation, respectively, and attenuates the tumor-suppression activity of merlin (48,49). Over 90 % of cancer cells are derived from epithelial cells, where trace amounts of CPI-17 are expressed (35,36). The role of CPI-17 in normal epithelium remains to be investigated.

Functions of other CPI-17 family members

PHI: Both PHI-1 and -2 are products of the phospholipase C-neighboring gene (PNG, PPP1R14B) (50). PNG was originally discovered on chromosome 11 as a candidate gene involved in multiple endocrine neoplasia type 1, although later studies eliminated that possibility. Two potential initiation ATG sequences exist in the PNG transcript (11,50). Initiation at the first ATG yields a 203-residue polypeptide, named PHI-2, whereas the other
in-frame ATG initiates translation for the 147-residue PHI-1 (Fig. 1A, red triangle) (11). PHI-1 is ubiquitously and abundantly expressed in various tissues and cultured cells. In contrast, PHI-2 expression is restricted to muscle tissues (11). Immunohistochemical analysis showed a significant difference between CPI-17 and PHI-1/2 localization, with the antibody recognizing both PHI-1 and PHI-2 heavily staining skeletal muscle capillary endothelium and the juxtamembrane region of the ileac smooth muscle layer (51). Recombinant PHI-1 inhibits PP1 and the purified MLCP complex upon phosphorylation at Thr57 (11). Phosphorylated PHI-1 evokes contraction of skinned smooth muscle strips (52). However, the inhibitory potency of PHI-1 for the MLCP complex (IC$_{50}$ = 50 nM) is significantly lower compared to CPI-17 (IC$_{50}$ = 1 nM), suggesting novel target PP1 holoenzymes for PHI-1. Purified PKC and ROCK are capable of phosphorylating PHI-1 at Thr57 and other undetermined site(s) (52), whereas ILK exclusively phosphorylates PHI-1 at Thr57 (52). Activation of G-proteins in smooth muscle tissues induces the phosphorylation of endogenous PHI-1 (53,54). On the other hand, reconstitution of unphosphorylated PHI-1 does not restore phorbol ester-induced contraction of CPI-17-null chicken smooth muscle (39). Therefore, PHI-1 is not involved in PKC-mediated MLCP inhibition. The endothelial expression of PHI-1 is involved in cell migration (55). Endogenous PHI-1 accumulates at the leading edge of endothelial cells, and gene silencing of PHI-1 can retard cell migration. Interestingly, PHI-1 knockdown does not affect the phosphorylation status of MLCP-substrate proteins, such as myosin light chain and ezrin/radixin/moesin (55), suggesting that PHI-1 controls a novel subset of PP1 holoenzymes in endothelial cells.

KEPI and GBPI: KEPI (PPP1R14C, chromosome 6) was discovered as a protein that is up-regulated in brain tissue isolated from morphine-addicted mice (12). In terms of amino acid sequence KEPI seems to be more closely related to PHI-1 than CPI-17. The phosphorylation of KEPI at Thr75 by PKC is sufficient to convert this protein into a potent PP1 inhibitor (12). A PP1-binding motif (-KVFF-) exists in the N-terminal tail of KEPI (Fig. 1A, green box). Indeed, PP1 co-precipitates with beads conjugated with unphosphorylated KEPI (56). Purified PKC and ILK phosphorylates recombinant KEPI at Thr73, the inhibitory phosphorylation site (12,57). Phospho-KEPI inhibits the purified MLCP complex and isolated PP1 with an IC$_{50}$ of 8 nM and 0.1 nM, respectively (57). Therefore, phospho-KEPI potently inhibits the PP1 holoenzyme, but the N-terminal KVFF sequence of KEPI may affect its inhibitory potency. Recently, KEPI was re-discovered in a group of genes that are down-regulated in breast tumor cells, along with a known tumor suppressor, phosphatase and tensin homolog (PTEN) (58). Ectopic expression of KEPI in MCF7 cells induces up-regulation of PTEN via augmentation of ERK1/2 phosphorylation. Interestingly, although both CPI-17 and KEPI are involved in ERK1/2 phosphorylation, there is a clear contrast in their downstream signals (48,58), suggesting different pools of target PP1 holoenzymes may exist for each inhibitor. GBPI (PPP1R14D, chromosome 15) was discovered as a homologue of KEPI (13). The gene transcribes two splicing variants, GBPI and GBPI-2 (Fig. 1A). GBPI includes an intact PHIN domain whose sequence is 35% identical to CPI-17. On the other hand, the testis-specific GBPI-2 mRNA includes a frameshift at the A-B loop, and as such is unlikely to inhibit PP1. GBPI phosphorylated by PKC inhibits isolated PP1 with an IC$_{50}$ value of 3 nM. Phosphorylation of GBPI with PKA eliminates its inhibitory potency. A PP1-binding motif, KVHW, is found in the N-terminal tail (Fig. 1A, green box), which is necessary for the inhibition of the isolated PP1 catalytic subunit (13). Whether GBPI is capable of inhibiting PP1 holoenzymes has yet to be tested. Interestingly, GBPI enhances PP2A activity following its phosphorylation by PKC (13).

Cellular regulation of PP1 holoenzymes via PP1 inhibitor proteins

After the discovery of CPI-17 and CPI-17 family members, it becomes clear that PP1 inhibitor proteins characterized previously also engage in the control of cellular PP1 holoenzymes in the absence of subunit dissociation. For example, PP1 inhibitor-2 (I-2) inhibits a complex of PP1 and a microtubule-binding kinase, Nek2 through the conserved C-terminal domain of I-2 (59), which directly docks at the active site of PP1 in the co-crystal model of the PP1•I-2 complex (60). In addition, PP1 inhibitor-1 and inhibitor-3 also inhibit PP1 holoenzymes (reviewed in (3)). Thus, each PP1 inhibitor protein may target a specific subset of PP1 holoenzymes, and there are more PP1 inhibitor proteins that transduce kinase signals into phosphatases, as over 100 polypeptides function as PP1 regulatory subunits. A proteomic approach (“PP1 inhibitome”) will be useful
to gain a full understanding of the specific combinations of kinases, PP1 holoenzymes and inhibitor proteins. As discussed here, CPI-17 as well as other PP1 inhibitor proteins plays vital roles in signal transduction controlling both amplitude and duration of phosphorylation. Additional PP1 inhibitor proteins will surely be re-discovered as disease-causing genes, and recognized as novel therapeutic targets.

Acknowledgement
I apologize to the many investigators in the field whose original works could not be recognized in this Minireview.
References

1. Cohen, P. T. (2002) *J.Cell.Sci.* **115**, 241-256.
2. Ceulemans, H., and Bollen, M. (2004) *Physiol.Rev.* **84**, 1-39.
3. Virshup, D. M., and Shenolikar, S. (2009) *Mol. Cell* **33**, 537-545.
4. Matsumura, F., and Hartshorne, D. J. (2008) *Biochem.Biophys.Res.Commun.* **369**, 149-156.
5. Terrak, M., Kerff, F., Langsetmo, K., Tao, T., and Domínguez, R. (2004) *Nature* **429**, 780-784.
6. Somlyo, A. P., and Somlyo, A. V. (2003) *Physiol.Rev.* **83**, 1325-1358.
7. Surks, H. K., Mochizuki, N., Kasai, Y., Georgescu, S. P., Tang, K. M., Ito, M., Lincoln, T. M., and Mendelsohn, M. E. (1999) *Science* **286**, 1583-1587.
8. Richards, C. T., Ogut, O., and Brozovich, F. V. (2002) *J.Biol.Chem.* **277**, 4422-4427.
9. Eto, M., Ohmori, T., Suzuki, M., Furuya, K., and Morita, F. (1995) *J.Biochem.* **118**, 1104-1107.
10. Eto, M., Senba, S., Morita, F., and Yazawa, M. (1997) *J.Biol.Chem.* **272**, 13312-13320.
11. Hayashi, Y., Senba, S., Yazawa, M., Brautigan, D. L., and Eto, M. (2001) *J.Biol.Chem.* **276**, 39858-39863.
12. Eto, M., Kitazawa, T., Masuzawa, F., Aikawa, S., Kirkbride, J. A., Isozumi, N., Nishimura, Y., Brautigan, D. L., and Ohki, S. Y. (2007) *Structure* **15**, 1591-1602.
13. Senba, S., Eto, M., and Yazawa, M. (1999) *J.Biochem.* **125**, 354-362.
14. Eto, M., Kitazawa, T., and Brautigan, D. L. (2004) *Proc.Natl.Acad.Sci.U.S.A.* **101**, 8888-8893.
15. Kitazawa, T., Eto, M., Woodsome, T. P., and Brautigan, D. L. (2000) *J.Biol.Chem.* **275**, 9897-9900.
16. Huang, J., Mahavadi, S., Sriwai, W., Hu, W., and Murthy, K. S. (2006) *Biochem.J.* **396**, 193-200.
17. Eto, M., Kitazawa, T., Yazawa, M., Mukai, H., Ono, Y., and Brautigan, D. L. (2001) *J.Biol.Chem.* **276**, 29072-29078.
18. Zemlickova, E., Johannes, F. J., Aitken, A., and Dubois, T. (2004) *Biochem.Biophys.Res.Commun.* **316**, 39-47.
19. MacDonald, J. A., Eto, M., Borman, M. A., Brautigan, D. L., and Haystead, T. A. J. (2001) *FEBS Letters* **493**, 91-94.
20. Takizawa, N., Koga, Y., and Ikebe, M. (2002) *Biochem.Biophys.Res.Commun.* **297**, 773-778.
21. Dimopoulos, G. J., Semba, S., Kitazawa, K., Eto, M., and Kitazawa, T. (2007) *Circ.Res.* **100**, 121-129.
22. Etter, E. F., Eto, M., Wardle, R. L., Brautigan, D. L., and Murphy, R. A. (2001) *J.Biol.Chem.* **276**, 34681-34685.
23. Kitazawa, T., Semba, S., Huh, Y. H., Kitazawa, K., and Eto, M. (2009) *J.Physiol.(Lond.)* **587**, 3587-3603.
24. Bonnevier, J., and Arner, A. (2004) *J.Biol.Chem.* **279**, 28998-29003.
25. Takizawa, N., Niiro, N., and Ikebe, M. (2002) *FEBS Letters* **515**, 127-132.
30. Ahn, J. H., McAvoy, T., Rakhilin, S. V., Nishi, A., Greengard, P., and Nairn, A. C. (2007) *Proc.Natl.Acad.Sci.U.S.A.* **104**, 2979-2984
31. Neppl, R. L., Lubomirov, L. T., Momotani, K., Pfitzer, G., Eto, M., and Somlyo, A. V. (2009) *J.Biol.Chem.* **284**, 6348-6360
32. Freitas, M. R., Eto, M., Kirkbride, J. A., Schott, C., Sassard, J., and Stoclet, J. C. (2009) *Fundam Clin Pharmacol* **23**, 169-178
33. Dubois, T., Howell, S., Zemlickova, E., Learmonth, M., Cronshaw, A., and Aitken, A. (2003) *Biochem.Biophys.Res.Commun.* **302**, 186-192
34. Bibb, J. A., Snyder, G. L., Nishi, A., Yan, Z., Meijer, L., Fienberg, A. A., Tsai, L. H., Kwon, Y. T., Girault, J. A., Czernik, A. J., Huganir, R. L., Hemmings, H. C., Jr., Nairn, A. C., and Greengard, P. (1999) *Nature* **402**, 669-671
35. Woodsome, T. P., Eto, M., Everett, A., Brautigan, D. L., and Kitazawa, T. (2001) *J. Physiol.* **535**, 553-564
36. Kim, J. I., Young, G. D., Jin, L., Somlyo, A. V., and Eto, M. (2009) *Histochem.Cell Biol.* **132**, 191-198
37. Eto, M., Bock, R., Brautigan, D. L., and Linden, D. J. (2002) *Neuron* **36**, 1145-1158
38. Kitazawa, T., Takizawa, N., Ikebe, M., and Eto, M. (1999) *J. Physiol.* **520**, 139-152
39. Kitazawa, T., Polzin, A. N., and Eto, M. (2004) *J. Physiol.* **557**, 515-528
40. Dakshinamurti, S., Mellow, L., and Stephens, N. L. (2005) *Pediatr.Pulmonol.* **40**, 398-407
41. Sakai, H., Chiba, Y., Hirano, T., and Misawa, M. (2005) *Mol.Pharmacol.* **68**, 145-151
42. Morin, C., Sirois, M., Echave, V., and Rousseau, E. (2008) *Am.J.Respir.Cell Mol.Biol.* **39**, 638-643
43. Ohama, T., Hori, M., Sato, K., Ozaki, H., and Karaki, H. (2003) *J.Biol.Chem.* **278**, 48794-48804
44. Xie, Z., Su, W., Guo, Z., Pang, H., Post, S. R., and Gong, M. C. (2006) *Cardiovasc.Res.* **69**, 491-501
45. Chang, S., Hypolite, J. A., DiSanto, M. E., Changolkar, A., Wein, A. J., and Chacko, S. (2006) *Am.J.Physiol.Renal Physiol.* **290**, F650-656
46. Kolosova, I. A., Ma, S.-F., Adyshev, D. M., Wang, P., Ohba, M., Natarajan, V., Garcia, J. G. N., and Verin, A. D. (2004) *Am J Physiol Lung Cell Mol Physiol* **287**, L970-980
47. Watanabe, Y., Ito, M., Kataoka, Y., Wada, H., Koyama, M., Feng, J., Shiku, H., and Nishikawa, M. (2001) *Blood* **97**, 3798-3805.
48. Jin, H., Sperka, T., Herrlich, P., and Morrison, H. (2006) *Nature* **442**, 576-579
49. Thurneysen, C., Opitz, I., Kurtz, S., Weder, W., Stahel, R. A., and Felley-Bosco, E. (2009) *Lung Cancer* **64**, 140-147
50. Lagercrantz, J., Carson, E., Larsson, C., Nordenskjold, M., and Weber, G. (1996) *Genomics* **31**, 380-384
51. Toustant, N. A., Mandell, J. W., Everett, A. D., and Brautigan, D. L. (2004) *Histochem.Cell Biol.* **121**, 343-350
52. Deng, J. T., Sutherland, C., Brautigan, D. L., Eto, M., and Walsh, M. P. (2002) *Biochem.J.* **367**, 517-524
53. El-Touhky, A., Given, A. M., Cochard, A., and Brozovich, F. V. (2005) *FEBS Lett.* **579**, 4271-4277
54. Pang, H., Guo, Z., Xie, Z., Su, W., and Gong, M. C. (2006) *Am.J.Physiol.Cell.Physiol.* **290**, C892-899
55. Toustant, N. A., and Brautigan, D. L. (2004) *J.Cell.Sci.* **117**, 5905-5912
56. Gong, J. P., Liu, Q. R., Zhang, P. W., Wang, Y., and Uhl, G. R. (2005) Neuroscience 132, 713-727
57. Erdodi, F., Kiss, E., Walsh, M. P., Stefansson, B., Deng, J. T., Eto, M., Brautigan, D. L., and Hartshorne, D. J. (2003) Biochem.Biophys.Res.Commun. 306, 382-387
58. Wenzel, K., Daskalow, K., Herse, F., Seitz, S., Zacharias, U., Schenk, J. A., Schulz, H., Hubner, N., Micheel, B., Schlag, P. M., Osterziel, K. J., Ozcelik, C., Scherneck, S., and Jandrig, B. (2007) Biol Chem 388, 489-495
59. Eto, M., Elliott, E., Prickett, T. D., and Brautigan, D. L. (2002) J.Biol.Chem. 277, 44013-44020
60. Hurley, T. D., Yang, J., Zhang, L., Goodwin, K. D., Zou, Q., Cortese, M., Dunker, A. K., and DePaoli-Roach, A. A. (2007) J.Biol.Chem. 282, 28874-28883

Footnote

* This work was supported by National Institutes of Health Grant HL083261.

1 The abbreviations used are: PP1, Ser/Thr protein phosphatase-1; MBS, myosin binding subunit; MLCP, myosin light chain phosphatase; MYPT1, myosin phosphatase-targeting subunit-1; CPI-17, C-kinase-activated PP1 inhibitor Mr=17 kDa; PHI, PP1 holoenzyme inhibitor; KEPI, Kinase C-enhanced PP1 inhibitor; GBPI, gastrointestinal- and brain-specific PP1 inhibitory protein, PKC, protein kinase C; ROCK, RhoA-activated coiled-coil kinase; ILK, integrin-linked kinase, PKA, protein kinase A; PKG, protein kinase G.

2 Supplemental figure for educational purposes.

Figure Legend

Fig. 1: CPI-17 family. (A) Schematic illustration of the CPI-17 family primary structure. The inhibitory phosphorylation site (red) is located in the conserved PP1 holoenzyme inhibitory (PHIN) domain (cyan box). Gray dots and green boxes indicate additional phosphorylation sites and PP1 binding motifs, respectively. (B) Electrostatic surface potential map of the CPI-17 family. The surface model of phospho-CPI-17 was used as a template, and putative models for other proteins were generated in-silico based on the sequence alignment. The surface modeling was performed by Altif Laboratories (Tokyo, Japan).

Fig. 2: A model for selective inhibition of MLCP by phospho-CPI-17. Upon phosphorylation of Thr38, CPI-17 undergoes a conformational change that results in a re-alignment of the four helices A-D (middle). Phospho-CPI-17 docks at the active site of MLCP and suppresses its activity (right). Other PP1 holoenzymes can dephosphorylate phospho-CPI-17 and neutralize its inhibitory potency.
Fig. 2: Selective regulation of MLCP by P-CPI-17

- Phosphorylation by PKC, ROCK
- Dephosphorylation by other PP1

- Association with P-CPI-17
- Inactive MLCP

- Smooth muscle contraction
- Long term synaptic depression